Return to site

Roche Partnering for Innovation Summit

The QuiO team was invited to Basel, Switzerland to attend Roche Partnering for Innovation Summit on October 4th, 2016.  QuiO was one of five outside companies invited to exhibit their solution, and CEO Alex Dahmani presented in front a crowd of Roche employees representing pharmaceuticals, diagnostics, clinical development and drug delivery.

The event focused on three key areas:

  1. Real World Data (RWD)
  2. Digital Connected Health
  3. Clinical Trials of the Future

QuiO’s smart injection devices and connected software align well with Roche’s perspective on future needs. These three areas of innovation apply not just to Roche, but across the biotech and pharmaceutical industry. Below are some of the most interesting insights from the event:

Real World Data (RWD)

  • RWD is now essential for successful clinical trials, market launches and commercial expansion (e.g labeling and reimbursement).
  • RWD is a core component of value-based pricing, where hospitals provide the outcomes data to payers and Pharma, enabling price adjudication for the treatment.
  • Value-based pricing doesn’t just apply to performance-based bonuses and rebates for defined response rates, but can also apply to specific indications or therapy combinations.

Digital Connected Health

  • The core value proposition of connected health devices is the continuous collection of objective data, as opposed to the periodic reporting of subjective data.
  • Deployment of new technologies in clinical trials or commercial programs requires buy-in from senior management in order to move beyond evaluation phase.

Clinical Trials of the Future

  • Regulators are much more open to novel trial designs and new technologies than ever before.
  • Treatment value needs to be expanded beyond clinical response to include patient preferences, patient satisfaction, and quality of life.
  • Trials should incorporate real world endpoints. For example, instead of just a breathing test for lung function, the ability to walk up the stairs should be determined.
  • Trials need to be decentralized, moving as much testing and treatment to the home or neighborhood clinics, thereby creating a truly patient-centric trial (as opposed to a site-centric trial).
  • Decentralized trials will increase patient recruitment rates due to greater convenience, as well as expand the patient pool to recruit from by widening the geographic inclusion criteria.
All Posts
×

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!

OKSubscriptions powered by Strikingly